Financing ·
SciSparc Ltd.'s subsidiary, NeuroThera Labs Inc., completed a C$5.4 million private placement financing on August 15…
SPRCSciSparc Ltd.
SciSparc Ltd.'s subsidiary, NeuroThera Labs Inc., completed a C$5.4 million private placement financing on August 15, 2026. SciSparc invested C$2.7 million, subscribing for 22,500,000 units at C$0.12 per unit, each comprising one common share and one warrant exercisable at C$0.16 for three years. Following the transaction, SciSparc holds approximately 44.6% of NeuroThera’s outstanding shares, with its stake valued at roughly C$30 million. The proceeds will support general working capital and administrative expenses. SciSparc Ltd. operates in the pharmaceutical industry, focusing on clinical-stage cannabinoid-based drug development for central nervous system disorders.